Adenovirus-mediated hPNPase(old-35) gene transfer as a therapeutic strategy for neuroblastoma.
 

Posts


Write a Post
02-10-09 08:05 AM
Anonymous
Adenovirus-mediated hPNPase(old-35) gene transfer as a therapeutic strategy for neuroblastoma.
Reply

Adenovirus-mediated hPNPase(old-35) gene transfer as a therapeutic strategy for neuroblastoma.

J Cell Physiol. 2009 Feb 6;

Authors: Van Maerken T, Sarkar D, Speleman F, Dent P, Weiss WA, Fisher PB

Current treatment options for neuroblastoma fail to eradicate the disease in the majority of high-risk patients, clearly mandating development of innovative therapeutic strategies. Gene therapy represents a promising approach for reversing the neoplastic phenotype or driving tumor cells to self-destruction. We presently studied the effects of adenovirus-mediated gene transfer of human polynucleotide phosphorylase (hPNPase(old-35)), a 3',5'-exoribonuclease with growth-inhibitory properties, in neuroblastoma cells. Transgene expression was driven by either the cytomegalovirus (CMV) promoter or by a tumor-selective promoter derived from progression elevated gene-3 (PEG-3). Our data demonstrate that efficient adenoviral transduction of neuroblastoma cells and robust transgene expression are feasible objectives, that the PEG-3 promoter is capable of selectively targeting gene expression in the majority of neuroblastoma cells, and that hPNPase(old-35) induces profound growth suppression and apoptosis of malignant neuroblastoma cells, while exerting limited effects on normal neural crest-derived melanocytes. These findings support future applications of hPNPase(old-35) for targeted gene-based therapy of neuroblastoma and suggest that combination with the PEG-3 promoter holds promise for creating a potent and selective neuroblastoma therapeutic. J. Cell. Physiol. (c) 2009 Wiley-Liss, Inc.

PMID: 19202553 [PubMed - as supplied by publisher]